FibroGen Inc (FGEN)
0.3919
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 15:50
FibroGen Total Assets (Quarterly): 264.42M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 264.42M |
| June 30, 2024 | 293.20M |
| March 31, 2024 | 365.87M |
| December 31, 2023 | 423.53M |
| September 30, 2023 | 460.43M |
| June 30, 2023 | 515.13M |
| March 31, 2023 | 538.54M |
| December 31, 2022 | 610.09M |
| September 30, 2022 | 608.84M |
| June 30, 2022 | 686.79M |
| March 31, 2022 | 745.93M |
| December 31, 2021 | 773.82M |
| September 30, 2021 | 850.51M |
| June 30, 2021 | 808.62M |
| March 31, 2021 | 787.30M |
| December 31, 2020 | 826.84M |
| September 30, 2020 | 812.02M |
| June 30, 2020 | 807.68M |
| March 31, 2020 | 824.38M |
| December 31, 2019 | 857.40M |
| September 30, 2019 | 893.96M |
| June 30, 2019 | 915.07M |
| Date | Value |
|---|---|
| March 31, 2019 | 812.40M |
| December 31, 2018 | 880.60M |
| September 30, 2018 | 855.64M |
| June 30, 2018 | 869.92M |
| March 31, 2018 | 867.61M |
| December 31, 2017 | 898.65M |
| September 30, 2017 | 894.89M |
| June 30, 2017 | 542.64M |
| March 31, 2017 | 441.76M |
| December 31, 2016 | 469.55M |
| September 30, 2016 | 486.21M |
| June 30, 2016 | 499.13M |
| March 31, 2016 | 442.54M |
| December 31, 2015 | 470.57M |
| September 30, 2015 | 499.25M |
| June 30, 2015 | 541.40M |
| March 31, 2015 | 435.54M |
| December 31, 2014 | 483.53M |
| September 30, 2014 | 344.38M |
| June 30, 2014 | 372.66M |
| December 31, 2013 | 296.95M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
264.42M
Minimum
Sep 2024
857.40M
Maximum
Dec 2019
643.07M
Average
716.36M
Median
Total Assets (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 6.851B |
| Arbutus Biopharma Corp | 140.44M |
| GlycoMimetics Inc | 15.70M |
| Cidara Therapeutics Inc | 162.33M |
| Cue Biopharma Inc | 44.81M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 466.12M |
| Shareholders Equity (Quarterly) | -243.67M |
| Debt to Equity Ratio | -0.2987 |
| Current Ratio | 1.283 |
| Net Debt Paydown Yield | -0.68% |